Synthesis and biological evaluation of 2-amino-1-thiazolyl imidazoles as orally active anticancer agents

[1]  Chi-Hung Lin,et al.  Synthesis and biological activities of 2-amino-1-arylidenamino imidazoles as orally active anticancer agents. , 2010, Journal of medicinal chemistry.

[2]  C. Chen,et al.  Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91. , 2010, Pharmacological research.

[3]  A. Eschalier,et al.  Animal models of chemotherapy-evoked painful peripheral neuropathies , 2009, Neurotherapeutics.

[4]  E. Perez.  Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance , 2009, Molecular Cancer Therapeutics.

[5]  C. Chen,et al.  Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. , 2008, International journal of pharmaceutics.

[6]  G. Nicolini,et al.  Neurotoxic effects of antineoplastic drugs: the lesson of pre-clinical studies. , 2008, Frontiers in bioscience : a journal and virtual library.

[7]  Y. Shu,et al.  Role of Biotransformation Studies in Minimizing Metabolism-Related Liabilities in Drug Discovery , 2008, The AAPS Journal.

[8]  Anurag Chaudhary,et al.  Combretastatin a-4 analogs as anticancer agents. , 2007, Mini reviews in medicinal chemistry.

[9]  T. Fojo,et al.  Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  S. Skvortsov,et al.  MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. , 2007, Cancer research.

[11]  J. Aisner.  Overview of the changing paradigm in cancer treatment: oral chemotherapy. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[12]  C. Chen,et al.  Impaired phagocytosis of capsular serotypes K1 or K2 Klebsiella pneumoniae in type 2 diabetes mellitus patients with poor glycemic control. , 2006, The Journal of clinical endocrinology and metabolism.

[13]  J. Kraus,et al.  Imino-tetrahydro-benzothiazole derivatives as p53 inhibitors: discovery of a highly potent in vivo inhibitor and its action mechanism. , 2006, Journal of medicinal chemistry.

[14]  G. Giannini,et al.  Novel combretastatin analogues endowed with antitumor activity. , 2006, Journal of medicinal chemistry.

[15]  Giovanni Sorba,et al.  Medicinal chemistry of combretastatin A4: present and future directions. , 2006, Journal of medicinal chemistry.

[16]  H. Hsieh,et al.  BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo , 2004, Cancer Research.

[17]  N. Katsumata.  Docetaxel: an alternative taxane in ovarian cancer , 2003, British Journal of Cancer.

[18]  B. Bhattacharyya,et al.  Antimicrotubular drugs binding to vinca domain of tubulin , 2003, Molecular and Cellular Biochemistry.

[19]  C. Bedell,et al.  A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. , 2003, Clinical journal of oncology nursing.

[20]  M. Jordan,et al.  Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. , 2003, Cancer research.

[21]  Hans-Joachim Böhm,et al.  A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.

[22]  Chi-Hung Lin,et al.  Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. , 2003, Journal of medicinal chemistry.

[23]  R Scott Obach,et al.  Biotransformation reactions of five-membered aromatic heterocyclic rings. , 2002, Chemical research in toxicology.

[24]  J. Schellens,et al.  The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery , 2000, Investigational New Drugs.

[25]  N. Lawrence,et al.  Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle , 1998, Medicinal research reviews.

[26]  L. Vrang,et al.  Synthesis and antiviral activity of prodrugs of the nucleoside 1-[2',3'-dideoxy-3'-C-(hydroxymethyl)-beta-D-erythropentofuranosyl] cytosine. , 1998, Bioorganic & medicinal chemistry.

[27]  R. Himes,et al.  Effect of solution variables on the binding of vinblastine to tubulin. , 1988, Biochemical pharmacology.

[28]  Y. Kawamura,et al.  Synthesis and antifungal activity of a series of novel 1,2-disubstituted propenones. , 1987, Journal of medicinal chemistry.

[29]  F. Arsenyan,et al.  Imidazole derivatives XVIII. Synthesis and antitumor activity of some bis[2-chloroethyl]amino imidazole derivatives , 1984, Pharmaceutical Chemistry Journal.

[30]  R. Mcmahon,et al.  The enzymatic N-hydroxylation of an imine. A new cytochrome P-450-dependent reaction catalyzed by hepatic microsomal monooxygenases. , 1971, The Journal of biological chemistry.

[31]  S. Schmidt,et al.  Über Reaktionen von α‐Halogen‐keto‐Verbindungen mit dem Guanidin‐System, III. Synthese und Reaktivität der 2‐Amino‐1‐[thiazolyl‐(2)]‐imidazole , 1971 .

[32]  A. Seligman,et al.  Synthesis of potential anticancer agents. , 1967, Journal of medicinal chemistry.

[33]  H. Beyer,et al.  Über Thiazole, XL. Synthesen von Thiazolyl‐(2)‐guanidinen , 1962 .

[34]  L. Bennett,et al.  Synthesis of Potential Anticancer Agents. IV. 4-Nitro- and 4-Amino-5-imidazole Sulfones , 1957 .

[35]  R. Carlson.  New tubulin targeting agents currently in clinical development. , 2008, Expert opinion on investigational drugs.

[36]  E. Hamel.  Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin , 2007, Cell Biochemistry and Biophysics.

[37]  I. E. Kuppens.  Current state of the art of new tubulin inhibitors in the clinic. , 2006, Current clinical pharmacology.

[38]  Paraskevi Giannakakou,et al.  Targeting microtubules for cancer chemotherapy. , 2005, Current medicinal chemistry. Anti-cancer agents.

[39]  Jie Hu,et al.  Technological Advances in High-Throughput Screening , 2004, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[40]  Longgui Wang,et al.  The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review , 1999, Cancer Chemotherapy and Pharmacology.

[41]  D. Budman.  Vinorelbine (Navelbine): a third-generation vinca alkaloid. , 1997, Cancer investigation.